Citations to this article

Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
E Cadman, F Eiferman
E Cadman, F Eiferman
Published September 1, 1979
Citation Information: J Clin Invest. 1979;64(3):788-797. https://doi.org/10.1172/JCI109525.
View: Text | PDF
Research Article Article has an altmetric score of 3

Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.

Abstract

Synergistic killing of L1210 cells occurs when methotrexate (MTX) is administered just before 1-beta-D-arabinofuranosylcytosine (Ara-C). This pehnomenon is dependent upon both the dose and time of exposure to MTX. Such increased killing of cells can be explained by the enhanced intracellular accumulation of Ara-C in cells exposed to MTX. This enhancement of Ara-C entry into cells was only observed when the dose of MTX was high enough (1, 10, and 100 muM) to result in free intracellular nondihydrofolate reductase-bound MTX. At the highest doses of MTX (10 and 100 muM) Ara-C triphosphate was increased eightfold and deoxycytidine triphosphate was decreased by 50%. Therefore, the maximum synergistic cell kill when MTX precedes Ara-C may be the consequence of greater inhibition of DNA polymerase by th;e increased Ara-C triphosphate in the presence of the decreasing natural substrate of this enzyme, deoxycytidine triphosphate. Enhanced Ara-C accumulation after administration of MTX was also observed in human acute myelogenous leukemia cells.

Authors

E Cadman, F Eiferman

×

Total citations by year

Year: 2017 2011 2010 2009 2008 2006 2005 2003 2002 2001 2000 1998 1993 1992 1991 1990 1989 1988 1987 1986 1985 1984 1983 1982 1981 Total
Citations: 1 1 1 1 1 1 1 1 2 1 1 1 2 1 3 4 2 2 1 1 4 1 3 1 3 41
Citation information

Citations to this article (41)

Title and authors Publication Year
Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use
OA OConnor, J Amengual, D Colbourn, C Deng, A Sawas 		Leukemia & Lymphoma 2017
Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
M Casanova, A Medina-Pérez, M Moreno-Beltran, M Mata-Vazquez, A Rueda 		Therapeutics and Clinical Risk Management 2011
Adult Acute Lymphocytic Leukemia
AS Advani, HM Lazarus 		2010
Pralatrexate, a new hope for aggressive T-cell lymphomas?
A Rueda, M Casanova, C Quero, Á Medina-Pérez 		Clinical and Translational Oncology 2009
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
A Moricke, A Reiter, M Zimmermann, H Gadner, M Stanulla, M Dordelmann, L Loning, R Beier, WD Ludwig, R Ratei, J Harbott, J Boos, G Mann, F Niggli, A Feldges, G Henze, K Welte, JD Beck, T Klingebiel, C Niemeyer, F Zintl, U Bode, C Urban, H Wehinger, D Niethammer, H Riehm, M Schrappe 		Blood 2008
Pralatrexate: an emerging new agent with activity in T-cell lymphomas
OA OʼConnor 		Current Opinion in Oncology 2006
Hematopoietic stem cell gene therapy with drug resistance genes: an update
T Budak-Alpdogan, D Banerjee, JR Bertino 		Cancer Gene Therapy 2005
Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis
LE Abrey, CH Moskowitz, WP Mason, M Crump, D Stewart, P Forsyth, N Paleologos, DD Correa, ND Anderson, D Caron, A Zelenetz, SD Nimer, LM DeAngelis 		Journal of Clinical Oncology 2003
Gene Therapy of Cancer
IV Lebedeva, CA Stein 		Gene Therapy of Cancer 2002
Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro
M Akutsu, Y Furukawa, S Tsunoda, T Izumi, K Ohmine, Y Kano 		Leukemia 2002
Value of High-Dose Cytarabine During Interval Therapy of a Berlin-Frankfurt-Munster–Based Protocol in Increased-Risk Children With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 Randomized Phase III Trial
F Millot, S Suciu, N Philippe, Y Benoit, F Mazingue, A Uyttebroeck, P Lutz, F Mechinaud, A Robert, P Boutard, G Marguerite, A Ferster, E Plouvier, X Rialland, C Behard, D Plantaz, MF Dresse, P Philippet, L Norton, A Thyss, N Dastugue, C Waterkeyn, E Vilmer, J Otten 		Journal of Clinical Oncology 2001
Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study
MB Harris, JJ Shuster, J Pullen, MJ Borowitz, AJ Carroll, FG Behm, B Camitta, VJ Land 		Leukemia 2000
Coexpression of Cytidine Deaminase and Mutant Dihydrofolate Reductase by a Bicistronic Retroviral Vector Confers Resistance to Cytosine Arabinoside and Methotrexate
CM Beauséjour, NL Le, S Létourneau, D Cournoyer, RL Momparler 		Human Gene Therapy 1998
Effects of 5-Fluorouracil and a Combination of Tegafur and Uracil (UFT) on Nucleotide Metabolism in L1210 Ascites Tumor
H Kakito, T Ohkubo, Y Kagawa, S Inagaki, K Sumida, K Ooi, M Higashigawa, M Sakurai 		Cancer Investigation 1993
Aphidicolin potentiates apoptosis induced by arabinosyl nucleotides in human myeloid leukemia cell lines
K Kuwakado, M Kubota, H Hirota, S Adachi, K Matsubara, Y Kasai, Y Akiyama, H Mikawa 		Biochemical Pharmacology 1993
Management in Neuro-Oncology
J Hildebrand 		1992
A pilot study of intermediate-dose methotrexate and cytosine arabinoside, “Spread-out” or “Up-front,” in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia a pediatric oncology group study
RA Krance, EM Newman, D Pinkel, Y Ravindranath, MB Harris, M Brecher, R Wimmer, JJ Shuster, VJ Land, J Pullen, W Crist 		Cancer 1991
Intracellular dCTP/ARA-CTP Ratio and the Cytotoxic Effect of ARA-C
H Kawasaki, H Kuwabara, H Hori, M Higashigawa, T Ohkubo, M Sakurai 		Cancer Investigation 1991
Primary non-Hodgkin's lymphoma of the central nervous system: Phase II study of chemotherapy (BVAM) prior to radiotherapy
EM Bessell, J Punt, J Firth, T Hope, I Holland, J Lowe 		Clinical Oncology 1991
Biochemical modulation of cytosine arabinoside
S Grant 		Pharmacology & Therapeutics 1990
Intracellular ribonucleotide pools of lymphoblastic leukemic cells in untreated and relapsed all children
H Kawasaki, H Hori, M Higashigawa, T Ookubo, M Sakurai 		Medical and Pediatric Oncology 1990
Characterization of repair inhibition by methotrexate of ethylmethanesulfonate-and ultraviolet irradiation-induced DNA damage in Chinese hamster cells
AH Borchers, JA Straw 		Biochemical Pharmacology 1990
Biochemical interactions between methotrexate and 1-?-d-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study
EM Newman, DG Villacorte, AM Testi, RA Krance, MB Harris, Y Ravindranath, D Pinkel 		Cancer Chemotherapy and Pharmacology 1990
Synergistic effect of methotrexate and 1-β-d-arabinofuranosylcytosine on the generation of DNA strand breaks in a human promyelocytic leukemia cell line
A Tanizawa, M Kubota, T Takimoto, T Kito, Y Akiyama, Y Kiriyama, H Mikawa 		Leukemia Research 1989
Purine and Pyrimidine Metabolism in Man VI
K Mikanagi, K Nishioka, WN Kelley 		1989
The metabolic basis for combination chemotherapy
LE Damon, EC Cadman 		Pharmacology & Therapeutics 1988
Sequence-dependent antitumor effect of VP-16 and 1-β-d-arabinofuranosylcytosine in L1210 ascites tumor
T Ohkubo, M Higashigawa, H Kawasaki, H Kamiya, M Sakurai, Y Kagawa, E Kakito, K Sumida, K Ooi 		European Journal of Cancer and Clinical Oncology 1988
In Vitro Effects of Tp5 Analogs on E-Rosette Formation and Cell Division
L Denes, B Szendex, J Ember, J Major, L Szporny, G Hajos, O Nyeki, I Schon, K Lapis, L Kisfaludy 		Immunopharmacology and Immunotoxicology 1987
Advances in rational combination chemotherapy
L E Damon, E C Cadman 		Cancer Investigation 1986
Enhanced production of intracellular ara-CTP after sequential use of methotrexate and I-β-D-arabinofuranosylcytosine
T Nobori, T Okubo, N Shimizu, H Kawasaki, T Sako, M Komada, H Hirota, H Kamiya, M Sakurai 		Leukemia Research 1985
Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists
WN Hait, GL Lee 		Biochemical Pharmacology 1985
Current issues in the management of children with acute lymphocytic leukaemia
D Pinkel 		Postgraduate medical journal 1985
Inhibition of growth of leukemic cells by inhibitors of calmodulin: Phenothiazines and melittin
WN Hait, L Grais, C Benz, EC Cadman 		Cancer Chemotherapy and Pharmacology 1985
Cancer Chemotherapy and Selective Drug Development
KR Harrap, W Davis, AH Calvert 		1984
The Pharmacology and Clinical Use of Methotrexate
J Jolivet, KH Cowan, GA Curt, NJ Clendeninn, BA Chabner 		New England Journal of Medicine 1983
Modulation of metabolism of cytosine arabinoside in L cells by antibody and complement
WT Shearer, CG Green, HJ Mettes 		Immunopharmacology 1983
Adrenal and Endocrine Tumors in Children
GB Humphrey, GB Grindey, LP Dehner, RT Acton, TJ Pysher 		1983
Studies on the mechanism of action of cytosine arabinoside
DW Kufe, PP Major 		Medical and Pediatric Oncology 1982
Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro
JA Streifel, SB Howell 		Proceedings of the National Academy of Sciences 1981
Synergistic and antagonistic interactions of methotrexate and 1-β-D-arabinofuranosylcytosine in hepatoma cells
RC Jackson, RJ Harkrader 		Biochemical Pharmacology 1981
Use of periodate and methylamine for the quantitation of intracellular 5-fluro-2′-deoxyuridine-5′-monophosphate by high-performance liquid chromatography
R Dreyer, E Cadman 		Journal of Chromatography A 1981

Advertisement